A

Aptevo Therapeutics

APVO

0.40000
USD
-0.0033
(-0.82%)
Market Closed
Volume
18,108
EPS
0
Div Yield
0
P/E
-0
Market Cap
3,330,723
Related Instruments
A
ARVN
-0.760
(-2.76%)
26.780 USD
A
AVDL
0.135
(0.83%)
16.490 USD
C
CDTX
-0.190
(-1.45%)
12.890 USD
C
CRVS
0.36000
(13.85%)
2.96000 USD
I
INSM
2.510
(3.45%)
75.330 USD
M
MGNX
0.23500
(6.28%)
3.98000 USD
R
RIGL
-0.552
(-5.22%)
10.030 USD
S
STOK
-0.200
(-1.34%)
14.720 USD
V
VKTX
-2.380
(-4.18%)
54.610 USD
News

Title: Aptevo Therapeutics

Sector: Healthcare
Industry: Biotechnology
Aptevo Therapeutics Inc is a clinical-stage, research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed using ADAPTIR modular protein technology platform. The versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.